Literature DB >> 28610956

Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C.

Tzu-Hua Chang1, Meng-Feng Tsai2, Chien-Hung Gow3, Shang-Gin Wu4, Yi-Nan Liu1, Yih-Leong Chang5, Sung-Liang Yu6, Hsing-Chen Tsai7, Shih-Wen Lin8, Yen-Wei Chen6, Po-Yen Kuo9, Pan-Chyr Yang1, Jin-Yuan Shih10.   

Abstract

The epithelial-mesenchymal transition (EMT) regulator, Slug, plays multifaceted roles in controlling lung cancer progression, but its downstream targets and mechanisms in promoting lung cancer progression have not been well defined. In particular, the miRNAs downstream of Slug in non-small cell lung cancer (NSCLC) remain undetermined. Here, we report that miR-137 is downstream of the EMT regulator, Slug, in lung cancer cells. Slug binds directly to the E-box of the miR-137 promoter and up-regulates its expression in lung cancer cells. Knockdown of miR-137 abolished Slug-induced cancer invasion and migration, whereas upregulation of miR-137 was found to trigger lung cancer cell invasion and progression by direct suppressing TFAP2C (transcription factor AP-2 gamma). Clinical data showed that lung adenocarcinoma patients with low-level expression of Slug and miR-137 but high-level expression of TFAP2C experienced significantly better survival. miR-137 is a Slug-induced miRNA that relays the pro-metastatic effects of Slug by targeting TFAP2C. Our findings add new components to the Slug-mediated regulatory network in lung cancer, and suggest that Slug, miR-137, and TFAP2C may be useful prognostic markers in lung adenocarcinoma.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epithelial-mesenchymal transition (EMT); Non-small cell lung cancer (NSCLC); Slug; TFAP2C; miR-137

Mesh:

Substances:

Year:  2017        PMID: 28610956     DOI: 10.1016/j.canlet.2017.06.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  A TFAP2C Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer.

Authors:  Vincent T Wu; Boris Kiriazov; Kelsey E Koch; Vivian W Gu; Anna C Beck; Nicholas Borcherding; Tiandao Li; Peter Addo; Zachary J Wehrspan; Weizhou Zhang; Terry A Braun; Bartley J Brown; Vimla Band; Hamid Band; Mikhail V Kulak; Ronald J Weigel
Journal:  Mol Cancer Res       Date:  2019-10-16       Impact factor: 5.852

2.  MiR-629-5p promotes the invasion of lung adenocarcinoma via increasing both tumor cell invasion and endothelial cell permeability.

Authors:  Yu Li; Huibiao Zhang; Lei Fan; Jiahui Mou; Yue Yin; Chao Peng; Yuxiang Chen; Henglei Lu; Liting Zhao; Zhouteng Tao; Jing Chen; Yizheng Wang; Xinming Qi; Ruimin Huang; Jin Ren
Journal:  Oncogene       Date:  2020-02-27       Impact factor: 9.867

3.  Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.

Authors:  Yue Fu; Xinchun Liu; Qiuyang Chen; Tongtai Liu; Cheng Lu; Jun Yu; Yi Miao; Jishu Wei
Journal:  J Exp Clin Cancer Res       Date:  2018-07-03

Review 4.  Functional Role of Non-Coding RNAs during Epithelial-To-Mesenchymal Transition.

Authors:  Almudena Expósito-Villén; Amelia E Aránega; Diego Franco
Journal:  Noncoding RNA       Date:  2018-05-28

5.  Prognostic implications of decreased microRNA-101-3p expression in patients with non-small cell lung cancer.

Authors:  Hai-Min Lu; Wan-Wan Yi; Yu-Shui Ma; Wei Wu; Fei Yu; Heng-Wei Fan; Zhong-Wei Lv; Hui-Qiong Yang; Zheng-Yan Chang; Chao Zhang; Wen-Ting Xie; Jun-Jian Jiang; Ying-Chun Song; Li Chai; Cheng-You Jia; Gai-Xia Lu; Xiao-Jun Zhong; Li-Kun Hou; Chun-Yan Wu; Min-Xin Shi; Ji-Bin Liu; Da Fu
Journal:  Oncol Lett       Date:  2018-10-09       Impact factor: 2.967

6.  Exploration of the hub genes and miRNAs in lung adenocarcinoma.

Authors:  Yuanyuan Zhai; Yingli Chen; Qianzhong Li; Luqiang Zhang
Journal:  Oncol Lett       Date:  2019-06-14       Impact factor: 2.967

7.  The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis.

Authors:  Wei Wang; Xia-Bo Shen; Wei Jia; Da-Bing Huang; Yong Wang; Yue-Yin Pan
Journal:  Ther Adv Med Oncol       Date:  2019-05-23       Impact factor: 8.168

8.  Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer.

Authors:  James P De Andrade; Allison W Lorenzen; Vincent T Wu; Maria V Bogachek; Jung M Park; Vivian W Gu; Claire M Sevenich; Victoria C Cassady; Anna C Beck; Mikhail V Kulak; Robert A Robinson; Geeta Lal; Ronald J Weigel
Journal:  Oncotarget       Date:  2017-10-23

9.  MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.

Authors:  Guangbing Xiong; Hua Huang; Mengyu Feng; Gang Yang; Suli Zheng; Lei You; Lianfang Zheng; Ya Hu; Taiping Zhang; Yupei Zhao
Journal:  J Exp Clin Cancer Res       Date:  2018-04-03

10.  miR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1.

Authors:  Qi Song; Quanbo Ji; Jingbo Xiao; Fang Li; Lingxiong Wang; Yin Chen; Yameng Xu; Shunchang Jiao
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-01       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.